Across TCGA pan-cancer cohorts, IGLV9-49 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGLV9-49 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher IGLV9-49 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGLV9-49 expression acts as an unfavorable survival marker.

LUSC, SARC, and LUAD are the cancer types where IGLV9-49 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.758	<.001	36	view →
SARC	OS	Median	All	0.176	0.860	<.001	6	view →
LUAD	OS	Median	All	0.258	0.787	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGLV9-49 tumor-vs-normal RNA expression · all IGLV9-49 data types